SELLAS Life Sciences Group Inc - SLS STOCK NEWS

IMPACT

SENTIMENT

10/17/2023 08:45 AM

SLS : Nasdaq

SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting

IMPACT

SENTIMENT

10/12/2023 04:05 PM

SLS : Nasdaq

SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

IMPACT

SENTIMENT

10/11/2023 08:30 AM

SLS : Nasdaq

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

IMPACT

SENTIMENT

10/10/2023 04:15 PM

SLS : Nasdaq

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia

IMPACT

SENTIMENT

10/10/2023 07:00 AM

SLS : Nasdaq

GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

IMPACT

SENTIMENT

10/02/2023 05:04 PM

ATHX : Nasdaq SLS : Nasdaq RIGL : Nasdaq

Athersys Director Jane Wasman Appointed Board Chair

IMPACT

SENTIMENT

09/21/2023 08:30 AM

SLS : Nasdaq

SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

IMPACT

SENTIMENT

09/18/2023 04:19 PM

SLS : Nasdaq

SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

IMPACT

SENTIMENT

08/22/2023 08:30 AM

SLS : Nasdaq

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

IMPACT

SENTIMENT

08/10/2023 04:08 PM

SLS : Nasdaq

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

SELLAS Life Sciences Group Inc

Nasdaq:SLS

SLS Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

About SLS

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.